Clinical Focus Target institutions and partnerships in neurodegenerative disease spaces (Parkinson’s, Alzheimer’s, Friedreich’s ataxia) leveraging Retrotope's RT001 platform and its demonstrated mitochondrial protection to position for research collaborations and clinical trial support.

Privately Funded Stability Highlight retrotope’s private funding and Phase 1/2 safety in Friedreich’s ataxia to engage potential investors, CROs, and strategic partners seeking co-development opportunities with a financially stable, clinical-stage company.

Clinical Milestones Leverage ongoing and completed Phase 2 ALS study and preclinical RT011 data to create outreach for partnership in expanded indication exploration, companion diagnostics, and regulatory strategy advisory collaborations.

Global Collaboration Capitalise on the company’s extensive global collaboration network and science-centric branding to propose research alliances with academia, biotech centers, and contract research organizations for shared access to mechanistic insights and accelerated development.

Commercial Readiness Position RT001’s tissue-targeted delivery and safety profile to pharma buyers and specialty distributors focusing on high-barrier neurodegenerative therapies, with a plan for strategic manufacturing, supply continuity, and market access discussions.